Abstract
Fusobacterium nucleatum is a common oral commensal bacterium capable of severe invasive infections. We report a case of a diffuse bilateral pneumopathy with F. nucleatum-positive blood culture successfully treated by common antibiotics in a patient receiving eculizumab for a drug-induced thrombotic microangiopathy (TMA). It is the first described case of a severe F. nucleatum-associated infection in a patient undergoing terminal complement inhibitor therapy. We suggest providing preventive dental care before eculizumab initiation.
Keywords:
Eculizumab; Fusobacterium nucleatum; Periodontitis; Pneumopathy.
Copyright © 2019 Elsevier Ltd. All rights reserved.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Anus Neoplasms / complications
-
Anus Neoplasms / drug therapy
-
Bacteremia / etiology*
-
Complement Inactivating Agents / adverse effects
-
Complement Inactivating Agents / therapeutic use
-
Female
-
Fusobacterium Infections / diagnosis*
-
Fusobacterium Infections / drug therapy
-
Fusobacterium Infections / etiology*
-
Fusobacterium nucleatum* / genetics
-
Humans
-
Pneumonia, Bacterial / diagnosis*
-
Pneumonia, Bacterial / drug therapy
-
Pneumonia, Bacterial / etiology*
-
Tomography, X-Ray Computed
-
Ultrasonography, Doppler
Substances
-
Antibodies, Monoclonal, Humanized
-
Complement Inactivating Agents
-
eculizumab